VIARTIS

 

 

 PARKINSON'S DISEASE NEWS

 

 

 

 

 

Parkinson's Disease News covers all significant new research, reports, books, and resources concerning Parkinson's Disease. Articles are chosen on the basis of their medical significance or potential interest. Our overwhelming priority is the facts, regardless of whether they contradict prevailing views or vested interests. Analysis and further information are provided either to explain the background or implications, or to balance misleading claims. If you notice errors or inadequacies, or dispute what is written, or want to propose articles, please e-mail [email protected].

                                          

 

29th June 2014 - New research

COMPARISON OF L-DOPA, AGONISTS AND MAO INHIBITORS

Lancet [2014] Jun 10 [Epub ahead of print] (Pd Med Collaborative Group)  Complete abstract

Whether the initial treatment for Parkinson's disease should consist of L-dopa, dopamine agonists, or MAO B inhibitors is uncertain. So researchers aimed to establish which of these three classes of drug, as initial treatment, provided the most effective long-term control of symptoms and best quality of life for people with early Parkinson's Disease.

People newly diagnosed with Parkinson's disease were randomly assigned between the use of L-dopa, dopamine agonists and MAO B inhibitors. After three years PDQ-39 mobility scores averaged 18 points better in people assigned to L-dopa. PDQ-39 mobility scores were 14 points better in people assigned to MAO B inhibitors when compared to those taking dopamine agonists. L-dopa was not significantly advantageous for EQ-5D utility scores, dementia, admissions to institutions, and death rates. Treatments were discontinued in 28% of those taking dopamine agonists, 23% of those taking MAOB inhibitors, but only 2% of those taking L-dopa.

Small but persistent benefits are shown for patient-rated mobility scores when treatment is initiated with L-dopa compared with dopamine agonists and MAO B inhibitors. MAO B inhibitors were found to be at least as effective as dopamine agonists. L-dopa is also clearly more tolerable. For more news go to Parkinson's Disease News.

FOR A PRINTABLE OR WHITE BACKGROUND VERSION OF THIS ARTICLE CLICK HERE

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
2006-2014  Viartis
 
2015-07-19 19:32:19
 
[email protected]